Publication: Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Nature Publishing Group UK
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Nazha, A., M. A. Sekeres, R. Komrokji, D. P. Steensma, H. Kantarjian, G. Roboz, P. Fenaux, et al. 2017. “Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.” Blood Cancer Journal 7 (12): 644. doi:10.1038/s41408-017-0018-7. http://dx.doi.org/10.1038/s41408-017-0018-7.
Research Data
Abstract
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service